The tumor recall response of antitumor immunity primed by a live, recombinant Listeria monocytogenes vaccine comprises multiple effector mechanisms

Clin Immunol. 2001 Mar;98(3):346-57. doi: 10.1006/clim.2000.4987.

Abstract

Listeria monocytogenes, a facultative intracellular bacterium, can induce a potent antitumor immune response if engineered to express a model tumor antigen also expressed by the tumor cells. The effectiveness of this approach is dependent on L. monocytogenes-induced tumor-specific CD4(+) and CD8(+) T-cells. CD8(+) T-cells may mediate tumor eradication largely through direct CTL activity, but the role of CD4(+) T-cells and other cells of the immune system is less clear. Here we investigate their role and the role of the cytokines they produce in the ability of L. monocytogenes-induced antitumor immunity to protect against tumor challenge. Our results suggest that a complex cytokine response, involving type 2 as well as type 1 cytokines, is responsible for the ability of Lm-NP-immunized mice to resist tumor challenge, potentially mediating tumor cell killing through multiple effector pathways.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antigens, Neoplasm / immunology
  • Bacterial Vaccines / immunology*
  • Dendritic Cells / physiology
  • Immunization
  • Interleukin-4 / physiology
  • Listeria monocytogenes / immunology*
  • Lymphocyte Activation
  • Macrophages / physiology
  • Mice
  • Mice, Inbred BALB C
  • Neoplasms, Experimental / immunology*
  • T-Lymphocytes / immunology
  • Vaccines, Synthetic / immunology*

Substances

  • Antigens, Neoplasm
  • Bacterial Vaccines
  • Vaccines, Synthetic
  • Interleukin-4